CannaPharmaRX, Inc.

OTC: CPMD · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Calgary, ABCIK 0001081938Reports USD

#835 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

38D

FH 28DQ 48GM —SS 54

v0.1 · 55/100 weight · provisional

↑ listing tenure, disclosure history · ↓ balance-sheet leverage, filing timeliness

Methodology →

Revenue TTM

$1.7M

Rev growth YoY (TTM)

+46.4%

Net income (FY)

-$11.1M

Employees

Market cap

$1.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.4M$1.4M2025

Net income-$11.1M-$11.1M2025

Operating income-$3.3M-$3.3M2025

Total assets$7.0M$7.0M2025

Liabilities$37.2M$37.2M2025

Equity-$30.2M-$30.2M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY24

$820.1k

FY24

$1.4M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

CannaPharmaRX, Inc. booked $1.4M in FY2025 revenue, growing 66% year over year — faster than most Healthcare companies we track, at a -817.2% net margin.

Peers · Healthcare

Acro Biomedical Co., Ltd.16D SOHM, Inc.61C Meridian Holdings, Inc.——International Stem Cell Corporation57C

Key facts

CEOConstantine Nkafu

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersCalgary, AB

ExchangeOTC: CPMD

Employees26

IPO date1999-10-29

Latest filings

10-Q2026-05-20 10-K2026-03-31 8-K2026-01-13 8-K2025-12-18 10-Q2025-11-14 8-K2025-10-10 10-Q2025-08-14 10-Q2025-05-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.